Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $3.69 in the prior trading day, Chromadex Corp (NASDAQ: CDXC) closed at $2.95, down -20.05%. In other words, the price has decreased by $-20.05 from its previous closing price. On the day, 0.88 million shares were traded. CDXC stock price reached its highest trading level at $3.72 during the session, while it also had its lowest trading level at $2.8901.
Ratios:
Our goal is to gain a better understanding of CDXC by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.24. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.09.
On August 11, 2022, B. Riley Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $6 to $2.40.
On March 08, 2022, ROTH Capital started tracking the stock assigning a Buy rating and target price of $7.ROTH Capital initiated its Buy rating on March 08, 2022, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’23 when Gerber Brianna bought 5,000 shares for $1.41 per share. The transaction valued at 7,050 led to the insider holds 27,436 shares of the business.
Jaksch Frank L Jr bought 7,000 shares of CDXC for $11,830 on Jun 12 ’23. The Director now owns 231,339 shares after completing the transaction at $1.69 per share. On May 31 ’23, another insider, Fried Robert N, who serves as the Chief Executive Officer of the company, bought 7,000 shares for $1.42 each. As a result, the insider paid 9,940 and bolstered with 95,001 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDXC now has a Market Capitalization of 222161856 and an Enterprise Value of 254610880. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.66 while its Price-to-Book (P/B) ratio in mrq is 7.77. Its current Enterprise Value per Revenue stands at 3.047 whereas that against EBITDA is -55.701.
Stock Price History:
The Beta on a monthly basis for CDXC is 1.93, which has changed by 1.6934307 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, CDXC has reached a high of $4.65, while it has fallen to a 52-week low of $1.25. The 50-Day Moving Average of the stock is 10.51%, while the 200-Day Moving Average is calculated to be 66.32%.
Shares Statistics:
The stock has traded on average 297.56K shares per day over the past 3-months and 303940 shares per day over the last 10 days, according to various share statistics. A total of 74.98M shares are outstanding, with a floating share count of 44.68M. Insiders hold about 40.67% of the company’s shares, while institutions hold 15.49% stake in the company. Shares short for CDXC as of 1711584000 were 1315637 with a Short Ratio of 4.42, compared to 1709164800 on 1209959. Therefore, it implies a Short% of Shares Outstanding of 1315637 and a Short% of Float of 2.3599999.
Earnings Estimates
Chromadex Corp (CDXC) is presently subject to a detailed evaluation by ChromaDex Corporation analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $20.42, with high estimates of $2.86 and low estimates of $55.20.
